NCT00420303View on ClinicalTrials.gov

Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Spondylarthropathies, Enthesitis

Interventions

DRUG

Etanercept

50 mg injection once weekly

OTHER

Placebo

placebo

Trial Locations (15)

6202

Nice

12200

Berlin

13200

Arles

31000

Toulouse

33076

Bordeaux

34295

Montpellier

38130

Grenoble

45032

Orléans

67098

Strasbourg

75018

Paris (Bichat)

75651

Paris (Pitie Salpetriere)

75679

Paris (cochin)

84000

Avignon

446652

Herne

6229 HX

Maastricht

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00420303 - Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy | Biotech Hunter | Biotech Hunter